MedTrace Logo

A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster

NCT05492591 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-12-29

No results posted yet for this study

Summary

To evaluate the efficacy, optimal dose and efficacy trend of multiple subcutaneous injections of peginterferon α1b in patients with herpes zoster, and provide support for phase III clinical trials.

Conditions

  • Herpes Zoster

Interventions

DRUG

Peginterferon α1b

Injecting different doses of the peginterferon α1b into different groups of subjects.

DRUG

Peginterferon α1b with valacyclovir

Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.

DRUG

Valacyclovir

Valacyclovir is a positive control drug.

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Qianjin Lu · Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2023-07-22
Completion
2023-07-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05492591 on ClinicalTrials.gov